Results 181 to 190 of about 5,013 (195)

Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy

Oncology, 2023
Introduction: Dexamethasone (DEX)-sparing strategy with 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) and aprepitant (APR), as triplet antiemetic prophylaxis, is associated with poor control of delayed chemotherapy-induced nausea and vomiting (CINV)
Toshinobu Hayashi, M. Shimokawa, K. Matsuo, M. Uchiyama, K. Kawada, Takafumi Nakano, T. Egawa   +6 more
semanticscholar   +1 more source

Impact of body weight-based dosing of palonosetron and ondansetron on postoperative nausea and vomiting following laparoscopic sleeve gastrectomy: a randomized, double-blind study

Acta Chirurgica Belgica, 2023
Background Postoperative nausea and vomiting (PONV) is a frequent adverse effect following laparoscopic sleeve gastrectomy. Palonosetron with a standard dosing (75 μg) schedule has been questioned due to its low efficiency in obese patients.
Buşra Burcu, N. Hacım, O. Çalişkan, S. Demirgan, Talar Vartanoglu Aktokmakyan, Serhat Meric, T. Duymaz, O. Karabay, A. Solmaz   +8 more
semanticscholar   +1 more source

Analysis of the Efficacy and Safety of Palonosetron Hydrochloride in Preventing Nausea And Vomiting After TACE: A Retrospective Analysis.

Current Radiopharmaceuticals, 2023
PURPOSE To investigate the mechanism of nausea and vomiting after TACE, and analyze the efficacy and safety of palonosetron hydrochloride in the prevention of nausea and vomiting after TACE.
Haohao Lu, Chuansheng Zheng, B. Liang, X. Xia   +3 more
semanticscholar   +1 more source

Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT

Journal of Clinical Oncology
PURPOSE Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors.
Huaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang, Jun Yao, Shuang Leng, Xiumin Li, Li Lin, Jinping Chen, Songnan Zhang, Xia Qin, Zhiquan Qin, T. Yi, Ruoyu Wang, Xiang Li, Yan Yu, Zhenghua Wang, Qinhong Zheng, Jiazhuan Mei, Aimin Zang, Na Li, Feng Cao, Ke Cao, Weiwei Li, Yan Lu, Dang Lin, Yan Zhou, Runxiang Yang, W. Fang, N. Zhou, Yunpeng Yang, Yaxiong Zhang, Gang Chen, Ting Zhou, Xue Yang, Huan Wang, Yujiao Wang, Yan Huang, Li Zhang   +37 more
semanticscholar   +1 more source

A Randomized, Controlled Trial of Palonosetron Versus Ondansetron for Nausea, Vomiting, and Pruritus in Cesarean Delivery with Intrathecal Morphine

Anesthesia and Analgesia
BACKGROUND: Spinal anesthesia is the preferred anesthetic technique for cesarean deliveries. Postoperative nausea and vomiting (PONV) and pruritus occur in up to 80% and 83% of patients, respectively, after cesarean delivery with intrathecal opioids ...
T. Worravitudomsuk, S. Charuluxananan, W. Sukumpanumet, P. Sriprajittichai   +3 more
semanticscholar   +1 more source

Intraoperative Prophylaxis with Palonosetron for Postoperative Nausea and/or Vomiting in Adults Undergoing Cardiothoracic Surgery Under General Anesthesia: A Single-Center Retrospective Study.

Journal of Cardiothoracic and Vascular Anesthesia
OBJECTIVE This study assessed the efficacy of palonosetron, alone or with dexamethasone, in reducing postoperative nausea and/or vomiting (PONV) and its impact on hospitalization duration in patients who undergo adult cardiothoracic surgery (CTS) under ...
Carlos E Estrada Alamo, Suejean Hwangpo, Lisa Chamberlain, Connie Chon, B. Nair, V. O’Reilly-Shah, Sarah E. Bain, Justin S. Liberman   +7 more
semanticscholar   +1 more source

Newer rp-hplc method development and validation for the simultaneous estimultaneous estimation of fosnetupitant and palonosetron in dosage form

International Journal of Pharmaceuticals and Health Care Research
A novel, precise, accurate, rapid and cost effective isocratic reversephase high performance liquid chromatographic (RP-HPLC) method was developed, optimized and validated for the estimation of Fosnetupitant and Palonosetron in bulk and pharmaceutical ...
Tadala Venkata Kaivalya, Buddha.Sravana Sree, Cheepurupalli Prasad   +2 more
semanticscholar   +1 more source

Comparison between Palonosetron and Ondansetron in Prevention of Chemotherapy Induced Nausea Vomiting

The Journal of Sylhet Women's Medical College
Background: Chemotherapy induced nausea and vomiting (CINV) is the commonest and the most incapacitating experience of thepatient undergoing cancer chemotherapy. Poorly controlled CINV sometimes make patients to refuse further treatment. This study aimed
Tanni TA
semanticscholar   +1 more source

A Comparative Study of Palonosetron with Ondansetron for Prophylaxis of Postoperative Nausea and Vomiting (PONV) Following Laparoscopic Gynaecological Surgeries

Romanian Journal of Anaesthesia and Intensive Care, 2022
Background Incidence of postoperative nausea and vomiting (PONV) in susceptible patients can be unacceptably high (70–80% reported incidence). This study was designed to evaluate the effect of palonosetron and ondansetron in preventing PONV in high-risk ...
Rohit Balyan, Sachin Kumar, K. Lalitha, S. Aneja, Jai S. George   +4 more
semanticscholar   +1 more source

Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting

Current Medical Research and Opinion, 2022
Objective Cost-effectiveness analyses that consider all currently used antiemetics in the case of emetogenic chemotherapy-induced nausea and vomiting (CINV) have not been performed yet. We aim to compare the cost-effectiveness of olanzapine (OLA), or/and
S. Halloush, Abdullah A. Alhifany, N. Alkhatib, A. Q. Al Bawab, Batool S Al-Qawasmeh, Esra'a Al Shawakri, J. Koeller   +6 more
semanticscholar   +1 more source